比较18F-FDG PET / MRI，MRI和18F-FDG PET / CT在口咽和下咽鳞状细胞癌患者中检测同步性癌症和远处转移。,European Journal of Nuclear Medicine and Molecular Imaging

当前位置： X-MOL 学术 › Eur. J. Nucl. Med. Mol. Imaging › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

比较18F-FDG PET / MRI，MRI和18F-FDG PET / CT在口咽和下咽鳞状细胞癌患者中检测同步性癌症和远处转移。
European Journal of Nuclear Medicine and Molecular Imaging ( IF 8.6 ) Pub Date : 2019-10-12 , DOI: 10.1007/s00259-019-04510-5
Chih-Hua Yeh,Sheng-Chieh Chan,Chien-Yu Lin,Tzu-Chen Yen,Joseph Tung-Chieh Chang,Sheung-Fat Ko,Kang-Hsing Fan,Hung-Ming Wang,Chun-Ta Liao,Shu-Hang Ng

目的

在这项前瞻性研究中，我们试图比较氟脱氧葡萄糖PET / MRI，MRI和PET / CT在检测口咽和下咽鳞状细胞癌（OHSCC）患者中的同步性癌症和远处转移中的临床效用。

方法

我们检查了198例经活检证实为OHSCC的同意接受化学放射治疗的患者。所有患者均在同一天接受预处理PET / MRI和PET / CT。对患者进行至少12个月的随访或直至死亡。使用McNemar的测试曲线和接收器操作特征（ROC）曲线分别比较PET / MRI，MRI和PET / CT的敏感性/特异性和诊断能力。

结果

我们确定了55例（27.7％）患有同步性癌症和/或远处转移的患者（受累部位：83个）。现场分析结果显示，PET / MRI的敏感性比MRI高15.7％（73.5％对57.8％，p <0.001），与PET / CT的敏感性（73.5％对69.9％）相比，高出3.6％。p = 0.083），而PET / CT的敏感性比MRI高12.1％（69.9％对57.8％，p = 0.012）。基于患者的ROC曲线分析表明，PET / MRI的曲线下面积大于MRI（0.930对0.905，p = 0.023）。MRI和PET / CT在诊断能力方面无显着差异（0.905与0.917，p = 0.469）和PET / MRI与PET / CT之间（0.930对0.917，p = 0.062）。

结论

在我们的队列中，PET / MRI显示出比MRI更高的诊断能力，与PET / CT相比，在检测OHSCC患者的同步性癌症或远处转移方面没有显着差异。

"点击查看英文标题和摘要"

Comparison of 18F-FDG PET/MRI, MRI, and 18F-FDG PET/CT for the detection of synchronous cancers and distant metastases in patients with oropharyngeal and hypopharyngeal squamous cell carcinoma.

Purpose

In this prospective study, we sought to compare the clinical utility of fluorodeoxyglucose PET/MRI, MRI, and PET/CT in the detection of synchronous cancers and distant metastases in patients with oropharyngeal and hypopharyngeal squamous cell carcinoma (OHSCC).

Methods

We examined 198 consecutive patients with biopsy-proven OHSCC who agreed to receive chemoradiation. All patients underwent pretreatment PET/MRI and PET/CT on the same day. Patients were followed-up for a minimum of 12 months or until death. The McNemar’s test and receiver-operating characteristic (ROC) curves were used to compare sensitivity/specificity and the diagnostic capabilities of PET/MRI, MRI, and PET/CT, respectively.

Results

We identified 55 patients (27.7%) who had synchronous cancers and/or distant metastases (number of involved sites: 83). The results of site-based analysis revealed that the sensitivity of PET/MRI was 15.7% higher than that of MRI (73.5% versus 57.8%, p < 0.001) and 3.6% higher compared with PET/CT (73.5% versus 69.9%, p = 0.083), whereas the sensitivity of PET/CT was 12.1% higher than that of MRI (69.9% versus 57.8%, p = 0.012). On a patient-basis, ROC curve analysis demonstrated that PET/MRI yielded a greater area under curve than MRI (0.930 versus 0.905, p = 0.023). There were no significant differences in terms of diagnostic capability between MRI and PET/CT (0.905 versus 0.917, p = 0.469) and between PET/MRI and PET/CT (0.930 versus 0.917, p = 0.062).

Conclusions

In our cohort, PET/MRI showed a significantly higher diagnostic capability than MRI and no significant difference compared with PET/CT for the detection of synchronous cancers or distant metastases in patients with OHSCC.

更新日期：2019-10-12

点击分享查看原文

点击收藏

阅读更多本刊新发论文本刊介绍/投稿指南